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Thromboembolism is a major complication of nephrotic syndrome. Renal vein
thrombosis and deep vein thrombosis are relatively common, especially in mem-
branous nephropathy. However, the incidence of portal vein and superior mesen-
teric vein (SMV) thrombosis in patients with nephrotic syndrome is very rare. To
date, several cases of portal vein thrombosis treated by anticoagulation therapy, not
by thrombolytic therapy, have been reported as a complication of nephrotic
syndrome. Here, we report a case of portal, splenic, and SMV thrombosis in a
patient with a relapsed steroid dependent minimal change disease who was treated
successfully with anticoagulation and thrombolytic therapy using urokinase. Radi-
ologic ﬁndings and his clinical conditions gradually improved. Six months later, a
complete remission of the nephrotic syndrome was observed and the follow-up
computed tomography scan showed the disappearance of all portal vein, splenic
vein, and SMV thrombi.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Venous thrombosis is one of the major life-threatening
complications of nephrotic syndrome. The pathophysiology of
thrombogenesis is not fully understood yet and the risk of
venous thrombotic complications varies according to age,
histologic type of renal disease, and level of serum albumin.
Deep venous thrombosis, renal vein thrombosis, and pulmonary
embolism are common in nephrotic syndrome, whereas portal
vein and superior mesenteric vein (SMV) thrombosis in nephro-
tic syndrome are rare. There were several cases of portal vein
thrombosis reported as a complication of nephrotic syndromen Society of Nephrology. Publi
c-nd/4.0/).
nal Medicine, Haeundae
icine, 875, Haeun-daero,
.treated with anticoagulation therapy alone. Here, we describe a
case of portal, splenic, and SMV thrombosis which occurred in a
patient with a relapsed steroid dependent minimal change
disease (MCD) and who was treated with anticoagulation and
thrombolytic therapy.Case report
A 31-year-old man presented to our hospital because of
severe diffuse abdominal pain and vomiting for the past 2 days.
He was diagnosed with MCD, which was conﬁrmed by renal
biopsy 4 years ago. He had been treated with corticosteroid
and cyclosporine 4 years ago and then stopped the corticos-
teroid treatment when complete remission was achieved.
However, relapse of nephrotic syndrome occurred soon, and
his medication was changed to tacrolimus and corticosteroid.shed by Elsevier. This is an open access article under the CC BY-NC-ND
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tained with tacrolimus. He had diffuse abdominal pain without
diarrhea, melena, or hematochezia. In addition, he had no history
of previous abdominal surgery and trauma. He was an ex-smoker
(5 pack-year) and he quit smoking 4 years ago. On physical
examination, his body temperature was 36.81C, blood pressure
140/70 mmHg, respiratory rate 26 breaths/min, and heart rate
102 beats/min. He gained weight of about 3 kg in 1 month. There
was diffuse and rebound tenderness on the abdomen and facial
edema and moderate pitting edema on lower limbs. Initial
laboratory data showed a relapsing nephrotic syndrome. Total
protein was 4.4 g/dL and serum albumin was 1.6 g/dL. His total
cholesterol was 489 mg/dL, and triglyceride was 270 mg/dL. The
urinalysis showed an isolated proteinuria and urine protein
creatinine ratio of 4,353 mg/g. Other laboratory results were as
follows: hemoglobin of 19.0 g/dL, hematocrit of 54.0%, white
blood cells of 10,280/mm3 and platelets of 157,000/mm3. The
blood urea nitrogen was 19.3 mg/dL and creatinine was 0.96 mg/
dL. The serum concentration of C-reactive proteinwas 1.75 mg/dL.
Enhanced abdomen computed tomography (CT) scan was
performed and showed diffuse portal, splenic, and SMV throm-
bosis accompanied with bowel edema probably due to bowel
ischemia (Fig. 1). We evaluated the coagulation status with
prothrombin time, activated partial thromboplastin time, D-dimer,Figure 1. The initial abdominal computed tomography (CT). Selected axi
massive thrombi within (A) the portal vein and (B) superior mesenteric veiﬁbrinogen, protein C, protein S, antithrombin III, antiphospholipid
antibody, and the factor V Leiden mutation. His prothrombin time
was 11.6 seconds, INR 1.03 (international normalized ratio, normal
range: 0.85–1.30), the activated partial thromboplastin time was
36.4 seconds and the antithrombin III was 48.6% (normal range:
80–120%). Protein C showed 163.2% (normal range: 72–150%) and
protein S 79.0% (normal range: 72–150%). Antiphospholipid anti-
body and factor V Leiden mutation were negative.
An intravenous infusion of unfractionated heparin was imme-
diately initiated as an anticoagulation therapy. Urokinase was
injected via selective catheterization of the superior mesenteric
artery (SMA) as thrombolytic therapy at the same time. An
angiography showed no visualization of the portal vein, SMV,
and splenic vein. The catheter was placed on the tip in the SMA
and a continuous thrombolytic therapy was started with uroki-
nase 50,000 IU/h. During the prolonged infusion of urokinase, the
follow-up SMV venography via the infusion catheter was per-
formed every 24 hours for 5 days. There was no visualization of
the main portal vein and SMV, but collateral vessel formationwas
observed at the follow-up SMV venography and symptoms were
gradually improved. Thrombolytic therapy was stopped and
anticoagulation therapy with heparin was switched to warfarin.
While anticoagulation with thrombolytic therapy was on-
going, we did not control the underlying nephrotic syndromeal and coronal images from the contrast-enhanced abdominal CT show
n (arrows).
Park et al / Nephrotic syndrome with thromboembolic complication 163because of infection risk and other complications related to
ischemic colitis. We started mycophenolate mofetil (1,000 mg/
d) and 1 mg/kg of prednisolone to control nephrotic syndrome
when the patient could eat food and was symptom free with
regards to his abdomen. Six months later, complete remission
(reduction of proteinuria to o300 mg/g) of the nephrotic
syndrome was maintained and the follow-up CT scan showed
disappearance of all portal vein, SMV, and splenic vein thrombi
(Fig. 2).Discussion
Venous thrombosis is a common and serious complication
in nephrotic syndrome. About 25% of nephrotic syndrome
patients suffer from systemic thromboembolic complications
[1]. It has been known why thromboembolic complications
increase in patients with nephrotic syndrome; the alterations
in coagulation factors, ﬁbrinolysis, and platelet function lead to
a hypercoagulability in nephrotic syndrome. In addition, low
levels of plasma albumin, dyslipidemia, and the therapeutic
use of diuretics and corticosteroids are thought to contribute
to the formation of thrombi [2,3].
SMV thrombosis is an uncommon and potentially lethal
disease because its presenting symptoms overlap with those
of many other diseases, leading to signiﬁcant delays in diagnosis
and therapy. Anticoagulation therapy alone could be sufﬁcient
in a mild form of portal and SMV thrombosis. The main
treatments of portal and SMV thrombosis are anticoagulation
and thrombolytic therapy and these should be considered and
started as soon as possible after diagnosis. Thrombolytic therapy
is a safe and effective method for patients with symptomatic
acute portal vein and SMV thrombosis, and urokinase is
currently the most established thrombolytic agent for venous
thrombosis [4,5]. Thrombolytic therapy can be administered
directly via percutaneous-transhepatic or transjugular-transhe-
patic routes or indirectly via SMA infusion of thrombolytic
agents. Direct thrombolytic therapy is more efﬁcient and
decreases the dose of the thrombolytic agent, lowering the risk
of related complications. However, an indirect method isFigure 2. Follow up computed tomography (CT) 6 months after treatm
thrombi of the portal vein (A) and superior mesenteric vein (B).technically easy compared to a direct method and there are
potential beneﬁts in infusing thrombolytic agents into small
mesenteric venous branches [6].
Venous thrombosis is a common complication of nephrotic
syndrome. However, the beneﬁcial effect of routine primary
prophylactic anticoagulation is uncertain. Advanced age, mem-
branous nephropathy, severe proteinuria, hypovolemia,
hypoalbuminemia, and dyslipidemia are all now recognized
to be correlated with an increased risk of thromboembolism
development. Therefore, primary prophylactic anticoagulation
needs to be carefully considered for such high-risk patients
and an acute mesenteric venous thrombosis should be sus-
pected when severe abdominal pain, vomiting, and ascites
develop in patients with nephrotic syndrome [7]. In this case,
although the patient had recurrent episodes of relapse, he was
young and had states of normoalbuminemia, euvolemia, and
mild proteinuria as an outpatient. Therefore, we did not give
prophylactic anticoagulation.
In our case, the patient’s abdominal pain continued and
worsened. However, there was no evidence of bowel perforation
or necrosis. We therefore immediately started anticoagulation
therapy and performed thrombolytic therapy simultaneously. An
immediate surgical intervention is needed if the patient is
suspected of having intestinal infarction and necrosis [4]. The
indirect thrombolytic therapy via SMA was successfully adminis-
tered and the patient’s symptoms improved, albeit the thrombi
remained. In SMA angiography, regression of the thrombi was
not observed, however, thrombolytic therapy prevents the pro-
gression of a thrombus formation and helps to develop a
collateral vessel formation that prevents the progression of
bowel ischemia. Six months later, we discontinued the antic-
oagulation, because a complete remission of the nephrotic
syndrome was maintained and the thrombi had disappeared.
In summary, the possibility of an acute portal vein or SMV
thrombosis should be considered when severe acute abdom-
inal pain and nausea occur in patients with nephrotic syn-
drome, especially in high risk patients. Anticoagulant therapy
with thrombolytic therapy should be considered and provided
when bowel ischemia or infarction is suspected. Interventional
treatment, including direct or indirect portal vein and SMVent. The follow up CT scan shows the disappearance of the occlusive
Kidney Res Clin Pract 33 (2014) 161–164164thrombolysis, is a safe and effective strategy for patients with
symptomatic acute portal vein and SMV thrombosis prior to
the development of bowel infarction.Conﬂict of interest
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